2 weeks Ago By ABMN Staff
Legal & General Group Plc lowered its stake in Innoviva, Inc. ( NASDAQ:INVA – Free Report ) by 6.0% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission.
The fund owned 173,969 shares of the biotechnology company’s stock after selling 11,056 shares during the period. Legal & General Group Plc owned 0.28% of Innoviva worth $3,018,000 at the end of the most recent quarter.
Other institutional investors and hedge funds have also made changes to their positions in the company. Dynamic Technology Lab Private Ltd acquired a new position in shares of Innoviva in the fourth quarter valued at about $750,000. Wells Fargo & Company MN lifted its stake in Innoviva by 40.
3% during the 4th quarter. Wells Fargo & Company MN now owns 37,022 shares of the biotechnology company’s stock valued at $642,000 after acquiring an additional 10,637 shares during the period. O Shaughnessy Asset Management LLC boosted its holdings in shares of Innoviva by 3.
2% in the 4th quarter. O Shaughnessy Asset Management LLC now owns 263,870 shares of the biotechnology company’s stock valued at $4,578,000 after acquiring an additional 8,240 shares during the last quarter. Arrowstreet Capital Limited Partnership raised its holdings in shares of Innoviva by 7.
6% during the fourth quarter. Arrowstreet Capital Limited Partnership now owns 1,146,243 shares of the biotechnology company’s stock worth $19,887,000 after purchasing an additional 81,142 shares during the last quarter. Finally, New Age Alpha Advisors LLC acquired a new position in Innoviva during the fourth quarter valued at $176,000.
99.12% of the stock is currently owned by institutional investors and hedge funds. Insider Buying and Selling In other Innoviva news, major shareholder Alexander J.
Denner sold 1,196,746 shares of the business’s stock in a transaction that occurred on Thursday, March 6th. The stock was sold at an average price of $17.52, for a total transaction of $20,966,989.
92. Following the completion of the sale, the insider now directly owns 5,658,705 shares in the company, valued at approximately $99,140,511.60.
The trade was a 17.46 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink .
1.70% of the stock is owned by insiders. Innoviva Trading Down 0.
7 % Innoviva ( NASDAQ:INVA – Get Free Report ) last issued its quarterly earnings results on Wednesday, February 26th. The biotechnology company reported $0.57 earnings per share (EPS) for the quarter.
The company had revenue of $91.81 million for the quarter. Innoviva had a return on equity of 20.
84% and a net margin of 18.31%. As a group, equities analysts predict that Innoviva, Inc.
will post 0.33 earnings per share for the current fiscal year. Analyst Ratings Changes INVA has been the subject of several analyst reports.
Scotiabank started coverage on Innoviva in a report on Friday, March 7th. They issued a “sector outperform” rating and a $55.00 price objective for the company.
StockNews.com lowered Innoviva from a “buy” rating to a “hold” rating in a research report on Tuesday. Get Our Latest Analysis on INVA Innoviva Profile ( Free Report ) Innoviva, Inc engages in the development and commercialization of pharmaceutical products in the United States and internationally.
The company’s products include RELVAR/BREO ELLIPTA, a once-daily combination medicine consisting of a LABA, vilanterol (VI), an inhaled corticosteroid (ICS), and fluticasone furoate; ANORO ELLIPTA, a once-daily medicine combining a long-acting muscarinic antagonist (LAMA) and umeclidinium bromide (UMEC) with a LABA, VI; GIAPREZA (angiotensin II), a vasoconstrictor to increase blood pressure in adults with septic or other distributive shock; XERAVA (eravacycline) for the treatment of complicated intra-abdominal infections in adults; and XACDURO, a beta lactamase inhibitor for the treatment of hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia. Read More Want to see what other hedge funds are holding INVA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Innoviva, Inc.
( NASDAQ:INVA – Free Report ). Receive News & Ratings for Innoviva Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Innoviva and related companies with MarketBeat.com's FREE daily email newsletter .
.
